Steve Perry's questions to CollPlant Biotechnologies (CLGN) leadership • Q2 2023
Question
The analyst asked about the timing and commercialization timeline for the dermal filler product, the size of the dermal filler market, and AbbVie/Allergan's potential market strategy for the new product.
Answer
The company cannot disclose specific timelines for the dermal filler program as it is led by their partner, AbbVie. They confirmed the program is in the clinical phase, has been in development for about 4 years, and is progressing as planned. They cited the current dermal filler market size as $5.5 billion with 10% annual growth. They could not comment on AbbVie's future market strategy for the product.